Nurix Therapeutics, Inc. Quarterly Debt-to-equity in % from Q2 2021 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Nurix Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q2 2021 to Q3 2024.
  • Nurix Therapeutics, Inc. Debt-to-equity for the quarter ending August 31, 2024 was 51.6 %, a 47.7% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 51.6 +16.7 +47.7% Aug 31, 2024
Q2 2024 52.8 +17.5 +49.5% May 31, 2024
Q1 2024 53.8 +15.6 +40.8% Feb 29, 2024
Q4 2023 43 +2.86 +7.13% Nov 30, 2023
Q3 2023 34.9 -5.68 -14% Aug 31, 2023
Q2 2023 35.3 -4.36 -11% May 31, 2023
Q1 2023 38.2 +2.76 +7.79% Feb 28, 2023
Q4 2022 40.1 +4.15 +11.5% Nov 30, 2022
Q3 2022 40.6 +5.35 +15.2% Aug 31, 2022
Q2 2022 39.7 +3.6 +9.98% May 31, 2022
Q1 2022 35.5 Feb 28, 2022
Q4 2021 36 Nov 30, 2021
Q3 2021 35.3 Aug 31, 2021
Q2 2021 36.1 May 31, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.